Trikafta/Kaftrio was Vertex Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $10.31B of $12.10B (85%).
| Product and Service | FY 2013 | FY 2015 | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2020 | FY 2020 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trikafta/Kaftrio | $7.69B | $8.94B | $10.24B | $10.31B | ||||||||||||||||||||
| Orkambi | — | — | — | — | ||||||||||||||||||||
| Other Product Revenues | $1.24B | $924.50M | $781.50M | $820.10M | ||||||||||||||||||||
| Product Revenues, Net | — | $30.20M | $35.70M | -$73.30M | ||||||||||||||||||||
| Kalydeco | — | — | — | — | ||||||||||||||||||||
| Alyftrek | — | — | — | $837.80M | ||||||||||||||||||||
| Symdeko/Symkevi | — | — | — | — | ||||||||||||||||||||
| Other | — | — | — | — | ||||||||||||||||||||
| Incivek | — | — | — | — | ||||||||||||||||||||
| Casgevy | — | — | $10.00M | $115.80M | ||||||||||||||||||||
| Journavx | — | — | — | $59.60M | ||||||||||||||||||||
| Other Revenues | — | — | — | $30.70M | ||||||||||||||||||||
| Collaborative & Royalty Revenues | — | — | — | — | ||||||||||||||||||||
| Total | $8.93B | $9.90B | $11.07B | $12.10B |
Vertex Pharmaceuticals brought in $12.10B from its seven product and service lines in fiscal 2025, the year ended December 31, 2025. Vertex Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $11.07B. Trikafta/Kaftrio was the largest at $10.31B (85.2%), ahead of Alyftrek at $837.80M (6.9%) and Other Product Revenues at $820.10M (6.8%). The other three lines brought in $206.10M combined.
Compared with fiscal 2024, Other Product Revenues grew 4.9% to $820.10M and Trikafta/Kaftrio grew 0.7% to $10.31B.
Vertex Pharmaceuticals began breaking out Alyftrek in fiscal 2025, Casgevy in fiscal 2024 and Journavx in fiscal 2025. The total is net of Product Revenues, Net, which took $73.30M off revenue in fiscal 2025.
United States was Vertex Pharmaceuticals’s largest region in fiscal 2025, bringing in $7.55B of $12.00B (63%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $5.70B | $6.04B | $6.68B | $7.55B | ||||||||||||
| Revenues | — | — | — | — | ||||||||||||
| Europe | $2.71B | $3.11B | $3.45B | $3.46B | ||||||||||||
| Other | $525.90M | $719.80M | $881.30M | $992.40M | ||||||||||||
| Outside Of The United States | — | — | — | — | ||||||||||||
| Total | $8.93B | $9.87B | $11.02B | $12.00B |
Vertex Pharmaceuticals brought in $12.00B from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 8.9% from $11.02B in fiscal 2024. United States was the largest at $7.55B (62.9%), ahead of Europe at $3.46B (28.8%) and Other at $992.40M (8.3%).
Compared with fiscal 2024, United States grew fastest, up 12.9% to $7.55B. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $8.93B to $12.00B, a compound annual growth rate of 10.4%. United States' share of the total fell from 63.8% to 62.9%.
Vertex Pharmaceuticals (VRTX) reports its revenue by product and service and by geography. In fiscal 2025, Trikafta/Kaftrio was its largest product and service line, bringing in $10.31B (85.2% of the total), followed by Alyftrek at $837.80M (6.9%).
Trikafta/Kaftrio was Vertex Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $10.31B, or 85.2% of the $12.10B total across its seven product and service lines.
United States was Vertex Pharmaceuticals' largest region in fiscal 2025, bringing in $7.55B, or 62.9% of the $12.00B total across its three regions.
Among Vertex Pharmaceuticals' regions that make up at least 2% of revenue, United States grew fastest in fiscal 2025, up 12.9% from $6.68B to $7.55B.
Every figure comes from Vertex Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Vertex Pharmaceuticals gives it, and years follow its fiscal calendar.
Vertex Pharmaceuticals' revenue by product and service goes back to fiscal 2013, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.